Revlimid vs Ibrance
Side-by-side drug price comparison from Medicare Part D data
Verdict
Ibrance costs 15% less per claim than Revlimid ($10816.00 vs $12786.00). Ibrance has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Ibrance at $4.5B.
| Metric | Revlimid | Ibrance |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786 | $10,816* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $4.5B |
| Total Claims | 612,000 | 418,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4% | -5.6%* |
| Generic Available | No | Yes |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 58,000 | 36,000 |
Ibrance costs 15% less per claim than Revlimid ($10816.00 vs $12786.00). Ibrance has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Ibrance at $4.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.